5th Jun 2015 15:46
Lifeline Scientific
("Lifeline" or the "Company")
Posting of Annual Report & Notice of AGM
Lifeline Scientific (AIM: LSIC), the transplantation technology company, confirms that the Annual Report and Accounts for the year ended 31 December 2014 ("2014 Annual Report and Accounts"), the Notice of the Annual General Meeting ("AGM") and a Form of Proxy were posted to shareholders on 28 May 2015.
The AGM is to be held at 8:30 am US CDT on 25 June 2015 at the Westin Hotel, 400 Park Boulevard, Itasca, IL 60143, USA.
A copy of the 2014 Annual Report and Accounts is available on the Company's website: www.lifeline-scientific.com
For further information:
Lifeline Scientific, Inc. | www.lifeline-scientific.com |
David Kravitz, CEO | Tel: +1 847 294 0300 |
Lisa Kieres, CFO | Tel: +1 847 294 0300 |
|
|
Panmure Gordon (UK) Limited | Tel: +44 (0)20 7886 2500 |
Freddy Crossley (Corporate Finance) |
|
Maisie Atkinson (Corporate Broking) |
|
|
|
Walbrook PR Limited | Tel: +44 (0) 20 7933 8780 or [email protected] |
Paul McManus | Mob: +44 (0)7980 541 893 |
Mike Wort | Mob: +44 (0)7900 608 002 |
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product, LifePort Kidney Transporter, is the global market-leading medical device for hypothermic machine preservation (HMP), of donor kidneys. LifePorts and novel solutions designed for preservation of other organs are in development, with LifePort Liver Transporter next in line for commercial launch. For more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to help improve kidney preservation, evaluation and transport prior to transplantation. It has been widely studied in clinical trials throughout the world and is the standard of care for machine preservation of kidneys. Employed by surgeons in over 190 leading transplant programmes in 28 countries, LifePorts have successfully preserved over 55,000 kidneys indicated for clinical transplant. For more information please visit www.organ-recovery.com
About LifePort Liver Transporter
LifePort Liver Transporter is modelled upon the clinically proven technology platform of LifePort Kidney Transporter. The Company's early liver HMP prototype was successfully used under a US FDA Investigational Device Exemption in clinical transplant studies by surgeons at New York-Presbyterian Hospital/Columbia University Medical Center. LifePort Liver Transporter and the Company's proprietary machine preservation solution, Vasosol®, are in the process of US and European regulatory registrations. The system is designed to help improve outcomes in liver transplantation by enabling the clinical use of hypothermic machine perfusion, and has been developed in consultation with clinical and research teams specializing in liver transplantation at Columbia University Medical Center and the University of Chicago. The system employs a rugged, streamlined ergonomic design for ease of use and transportability from donor bedside to recipient operating room. For more information please visit: http://www.organ-recovery.com/pipeline.php
Related Shares:
LSIC.L